Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

PRESS: U.S. IPOs Drag, Weighed Down by Brexit, Other Uncertainty <i>(Bloomberg BNA)</i>

PRESS: U.S. IPOs Drag, Weighed Down by Brexit, Other Uncertainty (Bloomberg BNA)

Related Content

FDA Approves First Gene Therapy for Rare Pediatric Immune Disorder Severe Leukocyte Adhesion Deficiency Type I

FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept)

Teva Receives FDA Approval of Denosumab Biosimilar and Filing Acceptances by FDA and EMA For Omalizumab Biosimilar

Amgen and Shanghai Henlius/Organon Settle Denosumab BPCIA Litigation

Formycon and Regeneron Settle European Aflibercept Biosimilar Litigation

Accord, Intas, and Bio-Thera File Four IPRs Against Janssen Golimumab Patents

Bio-Thera and Intas Expand Golimumab Biosimilar Partnership to India

Celltrion Announces AVTOZMA (tocilizumab-anoh) Now Available in U.S.

Goodwin Advises Obsidian Therapeutics on Merger With Galera Therapeutics and $350 Million Private Placement Financing

Goodwin Guides Piramal on Acquisition of Kenalog®

Goodwin Advises Tubulis on Acquisition by Gilead for $3.15 Billion Upfront and Up to $1.85 Billion in Milestones

Goodwin Advises Centerview and Guggenheim on $2.9 Billion Sale of Soleno Therapeutics to Neurocrine Biosciences

Ninth Circuit Ruling Could Open New Legal Line of Attack on Drugmakers (Law.com)

Factors Driving Change For Medtechs And Biotechs – A Legal View (In Vivo)

Goodwin Advises Centessa on Definitive Agreement to Be Acquired by Lilly for Up to $7.8 Billion

Goodwin Advises Transcend Therapeutics on IP Aspects of its Acquisition by Otsuka Pharmaceutical for Up to $1.225 Billion

Life Sciences

Technology

Capital Markets

Public Company Advisory Practice